VIDEO: Butler reviews benefits of patiromer observed in DIAMOND trial

ByJaved Butler, MD, MPH, MBA, FACC, FAHA, FESC

WASHINGTON — In this Healio video exclusive, Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC, discusses the results of the DIAMOND trial of patiromer for the reduction of hyperkalemia in patients with HF with reduced ejection fraction.

Butler, Cardiology Today Editorial Board Member, president of the Baylor Scott and White Research Institute, senior vice president for Baylor Scott and White Health and distinguished professor of medicine at the University of Mississippi, reviews the design of the DIAMOND trial and its main results.

As Healio previously reported, patiromer (Vifor Pharma), a novel potassium binder, was associated with reduced hyperkalemia in patients with HFrEF, which enabled an increase in adherence to optimal medical therapy.

Watch the video for more.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: The study was funded by Vifor Pharma. Butler reports financial ties with Abbott, Adrenomed, American Regent, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Corvia, CVRx, Eli Lilly, FIRE1, G3 Pharmaceutical, Impulse Dynamics, Janssen, LivaNova, Medtronic, Merck, Novartis, Novo Nordisk, Occlutech, Pfizer, Roche and Vifor Pharma.

American College of Cardiology

Read more

VIDEO: Butler reviews benefits of patiromer observed in DIAMOND trial

Related Content